Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 260 Carcinoma, Non-Small-Cell Lung 125 Glioblastoma 105 Breast Neoplasms 104 Ovarian Neoplasms 96 Carcinoma, Hepatocellular 88 Brain Neoplasms 71 Rectal Neoplasms 69 Neoplasm Metastasis 69 Lung Neoplasms 65 Colonic Neoplasms 58 Neoplasms 57 Glioma 52 Fallopian Tube Neoplasms 44 Carcinoma, Renal Cell 36 Gliosarcoma 31 Pancreatic Neoplasms 30 Melanoma 27 Liver Neoplasms 26 Stomach Neoplasms 21 Astrocytoma 21 Adenocarcinoma of Lung 21 Recurrence 20 Kidney Neoplasms 19 Colorectal Cancer Metastatic 17 Triple Negative Breast Neoplasms 16 Esophageal Neoplasms 15 Uterine Cervical Neoplasms 14 Sarcoma 13 Prostatic Neoplasms 13

Interventions

Sorafenib 2 nimotuzumab 1 lenvatinib 1 atezolizumab 1 Stents 1 Radiotherapy 1 Radiosurgery 1 Radiofrequency Ablation 1 Immune Checkpoint Inhibitors 1 Hematologic Tests 1 Ethiodized Oil 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × HCC × Bevacizumab × Clear all

NCT06823375 2026-03-04

SBRT With Immunotherapy and Atezo-Bev in HCC With Major Portal Vein Thrombosis

Chinese University of Hong Kong

Phase 2 Recruiting

HCC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡